Novel use of a chemically modified siRNA for robust and sustainable in vivo gene silencing in the retina.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
18 12 2020
Historique:
received: 27 07 2020
accepted: 03 12 2020
entrez: 19 12 2020
pubmed: 20 12 2020
medline: 29 4 2021
Statut: epublish

Résumé

Despite efficient and specific in vitro knockdown, more reliable and convenient methods for in vivo knockdown of target genes remain to be developed particularly for retinal research. Using commercially available and chemically modified siRNA so-called Accell siRNA, we established a novel in vivo gene silencing approach in the rat retina. siRNA designed for knockdown of the house keeping gene Gapdh or four retinal cell type-specific genes (Nefl, Pvalb, Rho and Opn1sw) was injected into the vitreous body, and their retinal mRNA levels were quantified using real-time PCR. Intravitreal injection of siRNA for Gapdh resulted in approximately 40-70% reduction in its retinal mRNA levels, which lasted throughout a 9-day study period. Furthermore, all the selected retinal specific genes were efficiently down-regulated by 60-90% following intravitreal injection, suggesting injected siRNA penetrated into major retinal cell types. These findings were consistent with uniform distribution of a fluorescence-labeled siRNA injected into the vitreous body. Interestingly, gene silencing of Grin1, a core subunit of NMDA receptor, was accompanied by significant prevention from NMDA-induced retinal ganglion cell death. Thus, we provide single intravitreal injection of Accell siRNA as a versatile technique for robust and sustainable in vivo retinal gene silencing to characterize their biological functions under physiological and pathophysiological conditions.

Identifiants

pubmed: 33339841
doi: 10.1038/s41598-020-79242-w
pii: 10.1038/s41598-020-79242-w
pmc: PMC7749170
doi:

Substances chimiques

NMDA receptor A1 0
RNA, Double-Stranded 0
RNA, Small Interfering 0
Receptors, N-Methyl-D-Aspartate 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

22343

Références

J Neurosci. 2009 Aug 5;29(31):9778-93
pubmed: 19657031
Nat Biotechnol. 2004 Mar;22(3):326-30
pubmed: 14758366
Circulation. 2012 Jun 26;125(25):3142-58
pubmed: 22661514
Biochem Biophys Res Commun. 2005 Jan 14;326(2):307-12
pubmed: 15582578
Invest Ophthalmol Vis Sci. 2017 Jun 1;58(7):2977-2990
pubmed: 28605809
Am J Pathol. 2004 Dec;165(6):2177-85
pubmed: 15579459
Brain Res. 2006 Apr 7;1081(1):211-8
pubmed: 16530172
Invest Ophthalmol Vis Sci. 2009 Mar;50(3):1329-35
pubmed: 18952918
Diabetes. 2006 Nov;55(11):3104-11
pubmed: 17065349
Mol Vis. 2012;18:874-86
pubmed: 22511849
Invest Ophthalmol Vis Sci. 1999 Sep;40(10):2391-7
pubmed: 10476807
Mucosal Immunol. 2010 Mar;3(2):193-205
pubmed: 19924119
J Biotechnol. 2012 Jan 20;157(2):326-33
pubmed: 22079868
J Pharmacol Sci. 2017 Sep 29;:
pubmed: 29110956
Mol Ther. 2010 Sep;18(9):1667-74
pubmed: 20571543
Cell Tissue Res. 2006 Nov;326(2):439-46
pubmed: 16862427
Acta Ophthalmol. 2010 Sep;88(6):652-9
pubmed: 20039857
J Neuroinflammation. 2017 Jan 19;14(1):14
pubmed: 28103888
Vision Res. 2007 Apr;47(9):1202-8
pubmed: 17292939
Sci Rep. 2020 Jan 22;10(1):969
pubmed: 31969611
Proc Natl Acad Sci U S A. 2004 Jan 6;101(1):16-22
pubmed: 14603031
PLoS One. 2019 May 31;14(5):e0217945
pubmed: 31150519
Eur J Clin Invest. 2011 Feb;41(2):221-32
pubmed: 20964680
Immunology. 2012 May;136(1):64-77
pubmed: 22260507
J Pathol. 2012 Jan;226(2):365-79
pubmed: 22069063
Invest Ophthalmol Vis Sci. 2019 May 1;60(6):2380-2387
pubmed: 31141609
Fundam Clin Pharmacol. 2020 Apr 16;:
pubmed: 32298491
Cell Death Differ. 2010 Jan;17(1):134-44
pubmed: 19696788
Graefes Arch Clin Exp Ophthalmol. 2000 Jun;238(6):486-90
pubmed: 10943672
Invest Ophthalmol Vis Sci. 2003 Jan;44(1):385-92
pubmed: 12506100
Vision Res. 2009 Mar;49(6):637-47
pubmed: 19948111
Curr Neurovasc Res. 2006 May;3(2):81-8
pubmed: 16719791
Sci Rep. 2019 Dec 31;9(1):20409
pubmed: 31892740
Brain Res. 2007 Dec 12;1184:306-15
pubmed: 17961520
Hum Mol Genet. 2012 Jul 1;21(13):2845-54
pubmed: 22434822

Auteurs

Takazumi Taniguchi (T)

Research and Development Division, Santen Pharmaceutical Co., Ltd., 8916-16 Takayama-cho, Ikoma-shi, Nara, 630-0101, Japan. takazumi.taniguchi@santen.com.

Ken-Ichi Endo (KI)

Research and Development Division, Santen Pharmaceutical Co., Ltd., 8916-16 Takayama-cho, Ikoma-shi, Nara, 630-0101, Japan.

Hidetoshi Tanioka (H)

Research and Development Division, Santen Pharmaceutical Co., Ltd., 8916-16 Takayama-cho, Ikoma-shi, Nara, 630-0101, Japan.

Masaaki Sasaoka (M)

Global Alliances and External Research, Santen Pharmaceutical Co., Ltd, Nara, Japan.

Kei Tashiro (K)

Department of Genomic Medical Sciences, Kyoto Prefectural University of Medicine, Kyoto, Japan.

Shigeru Kinoshita (S)

Department of Frontier Medical Science and Technology for Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan.

Masaaki Kageyama (M)

Global Alliances and External Research, Santen Pharmaceutical Co., Ltd, Nara, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH